QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)
QQQ   427.32 (-0.75%)
AAPL   181.56 (-0.41%)
MSFT   402.79 (-0.31%)
META   471.75 (-0.33%)
GOOGL   141.12 (+0.43%)
AMZN   167.08 (-1.43%)
TSLA   193.76 (-3.10%)
NVDA   694.52 (-4.35%)
NIO   5.96 (-2.93%)
AMD   165.69 (-4.70%)
BABA   73.15 (-1.03%)
T   16.92 (-0.29%)
F   12.26 (-0.33%)
MU   80.71 (+1.52%)
CGC   3.54 (-7.33%)
GE   148.62 (-0.36%)
DIS   109.44 (-1.94%)
AMC   4.67 (-3.52%)
PFE   27.60 (-0.07%)
PYPL   58.63 (-0.86%)
XOM   102.75 (-0.94%)

Relmada Therapeutics (RLMD) Earnings Date, Estimates & Call Transcripts

$5.96
+0.37 (+6.62%)
(As of 02/20/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

RLMD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RLMD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Relmada Therapeutics Analyst EPS Estimates

Current Year EPS Consensus Estimate:($3.33) EPS
Next Year EPS Consensus Estimate: ($3.55) EPS

RLMD Earnings Date and Information

Relmada Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 28th, 2024 based off prior year's report dates.

Relmada Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/28/2024
Estimated)
------- 
11/8/2023Q3 2023($0.95)($0.73)+$0.22($0.73)--
8/8/2023Q2 2023($0.92)($0.84)+$0.08($0.84)--
5/11/2023Q1 2023($0.88)($0.87)+$0.01($0.87)--
3/23/2023Q4 2022($1.33)($1.26)+$0.07($1.26)--
11/10/2022Q3 2022($1.40)($1.31)+$0.09($1.31)--
8/11/2022Q2 2022($1.30)($1.33)($0.03)($1.33)--  
5/5/2022Q1 2022($1.21)($1.40)($0.19)($1.40)--
3/23/2022Q4 2021($1.60)($1.80)($0.20)($1.80)--    
11/11/2021Q3 2021($1.62)($2.44)($0.82)($2.44)--    
8/10/2021Q2 2021($1.47)($1.56)($0.09)($1.56)--    
5/12/2021Q1 2021($1.38)($1.34)+$0.04($1.34)--  
3/22/2021Q4 2020($1.11)($1.31)($0.20)($1.28)--  












Relmada Therapeutics Earnings - Frequently Asked Questions

When is Relmada Therapeutics's earnings date?

Relmada Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 28th, 2024 based off last year's report dates. Learn more on RLMD's earnings history.

How much profit does Relmada Therapeutics generate each year?

Relmada Therapeutics (NASDAQ:RLMD) has a recorded net income of -$157.04 million. RLMD has generated -$3.70 earnings per share over the last four quarters.

What is Relmada Therapeutics's EPS forecast for next year?

Relmada Therapeutics's earnings are expected to decrease from ($3.33) per share to ($3.55) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:RLMD) was last updated on 2/20/2024 by MarketBeat.com Staff